GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » FCF Margin %

BIOA (Bioage Labs) FCF Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bioage Labs's Free Cash Flow for the three months ended in Dec. 2024 was $-5.14 Mil. Bioage Labs's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Bioage Labs's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Bioage Labs's current FCF Yield % is -37.62%.

The historical rank and industry rank for Bioage Labs's FCF Margin % or its related term are showing as below:


BIOA's FCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.86
* Ranked among companies with meaningful FCF Margin % only.


Bioage Labs FCF Margin % Historical Data

The historical data trend for Bioage Labs's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs FCF Margin % Chart

Bioage Labs Annual Data
Trend Dec22 Dec23 Dec24
FCF Margin %
- - -

Bioage Labs Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Bioage Labs's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioage Labs's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bioage Labs's FCF Margin % falls into.


;
;

Bioage Labs FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bioage Labs's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-51.888/0
= %

Bioage Labs's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-5.138/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioage Labs FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bioage Labs's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioage Labs Business Description

Traded in Other Exchanges
N/A
Address
1445A South 50th Street, Richmond, CA, USA, 94804
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Bioage Labs Headlines

From GuruFocus